Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-583-1 | CAS number: 108-44-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
Following oral application of m-toluidine hydrochloride in a limited study to male and female mice via food for 18 months and a post exposure observation period of 3 months, no tumour development was noted for female mice. In male mice m-toluidine hydrochloride led to an increase in liver tumours only at the lowest applied dose of 600 mg/kg bw/day when compared with pooled controls which is evaluated as questionable result by the authors (Weissburger 1978). After oral application of m-toluidine hydrochloride in a limited study male rats were dosed via food for 18 month followed by a post exposure observation time of 6 months. No tumour development was observed (Weisburger 1978). Therefore, the Beratergremium Umweltrelevanter Altstoffe (BUA,1993) concluded that a carcinogenic potency can be excluded for m-toluidine
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The study is not performed according to the criteria of today but provides reliable information.
- Principles of method if other than guideline:
- As described by Russfield AB et al. Toxicol appl Pharmacol 31, 47-51 (1975):
Application of the testsubstance via food for 18 month and then observed for 6 months. As the body weight gain was below that of controls by 10 %within 3 months a lowered dose was appied during 15 months treatment time. Gross necropsy and histological examination for tumour development. - GLP compliance:
- not specified
- Species:
- rat
- Strain:
- other: Charles River CD
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 4-6 weeks
- Housing: 2-3 per cage
- Diet ad libitum
- Water ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 - Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- Animals were given diets containing the different amounts of the compound for a period of 18 months; however, as the weight gain was below that observed in the corresponding controls by 10% or more (no details), the dosage was lowered for the remaining 15 month of treatment time..
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- During the course of the study the stability of the compound in the food was determined by mixing the chenical with the laboratrory chow, extracting the food mixture after 3 days with the appropriate solvent, and measuring the amount of compound which could be recovered.
- Duration of treatment / exposure:
- 78 weeks
- Frequency of treatment:
- daily
- Post exposure period:
- 6 months
- Remarks:
- Doses / Concentrations:
3 months: 8000, 16000 ppm (approx 400 and 800 mg/kg bw/day); 15 months: 4000, 8000 ppm (approx 200 and 400 mg/kg bw/day)
Basis: - No. of animals per sex per dose:
- 25
- Control animals:
- yes, plain diet
- Details on study design:
- Post-exposure period: 6 months
- Positive control:
- no data
- Observations and examinations performed and frequency:
- body weight development was followed carefully
- Sacrifice and pathology:
- Animals that died during the first 6 months were discarded without necropsy.
A complete necropsy was done on all animals that died after 6 months or were killed at the end of the experimental period and a histololgical examination was done on all grossly abnormal organs, tumor masses, lung, liver, spleen, kidneys, adrenal, heart, bladder, stomach, intestines, reproductive organs, pituitaries. - Other examinations:
- no further data
- Statistics:
- Exact test (Armitage, 1971),
Bonferroni correction,
Fisher exact test - Details on results:
- 400 and 800 mg/kg b.w./day for 3 months led to a reduced body weight gain (10 % and more) or death (no details). Therefore after the dosages were reduced to 200 and 400 mg/kg b.w./day for the remaining 65 weeks.
No tumors were observed. - Dose descriptor:
- dose level:
- Effect level:
- >= 200 - <= 800 mg/kg bw/day
- Sex:
- male
- Basis for effect level:
- other: no tumour development was observed
- Remarks on result:
- other: Effect type: carcinogenicity
- Executive summary:
In a long term study 400 and 800 mg/kg b.w./day m-toluidine hydrochloride was applied via food only to male rats for 3 months which led to a reduced body weight gain (10 % and more) or an increased mortality rate of the animals (no details). Therefore the dosages of m-toluidine in food were reduced to 200 and 400 mg/kg b.w./day for the remaining 65 weeks followed by a 6 month observation period without treatment. m-toluidine hydrochloride did not cause any tumors in male rats (Weisburger 1978).
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The study is not performed according to the criteria of today but provided reliable information.
- Principles of method if other than guideline:
- As described by Russfield AB et al. Toxicol appl Pharmacol 31, 47-51 (1975).
Application of the testsubstance via food for 18 month and then observed for 3 months. As the body weight gain was below that of controls by 10 % dosage was lowered during treatment time Gross necropsy and histological examination for tumour development. - GLP compliance:
- not specified
- Species:
- mouse
- Strain:
- CD-1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 4-6 weeks
- Housing: 5 per cage
- Diet ad libitum
- Water ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 - Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- Animals were given diets containing the different amounts of the compound for a period of 18 months. As the weight gain was below that observed in the corresponding controls by 10% or more, or if death occurred (no details) after 5 months treatment time, the dosage was lowered for the remaining 13 month treatment followed by a 3 months observation period without treatment.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- During the course of the study the stability of the compound in the food was determined by mixing the chenical with the laboratory chow, extracting the food mixture after 3 days with the appropriate solvent, and measuring the amount of compound which could be recovered.
- Duration of treatment / exposure:
- 78 weeks
- Frequency of treatment:
- daily
- Post exposure period:
- 3 months
- Remarks:
- Doses / Concentrations:
m/f, 5 months: 16000, 32000 ppm (approx. 2400 and 4800 mg/kg bw/day) m; 13 months: 4000, 8000 ppm (approx. 600 and 1200 mg/kg bw /day); f, 13 months: 8000, 16000 ppm (approx 1200 and 2400 mg/kg bw/day)
Basis: - No. of animals per sex per dose:
- 25
- Control animals:
- yes, plain diet
- Details on study design:
- Post-exposure period: 3 months
- Positive control:
- no data
- Observations and examinations performed and frequency:
- Body weights were followed carefully.
- Sacrifice and pathology:
- Animals that died during the first 6 months were discarded without necropsy.
A complete necropsy was done on all animals that died after 6 months or were killed at the end of the experimental period and a histololgical examination was done on all grossly abnormal organs, tumor masses, lung, liver, spleen, kidneys, adrenal, heart, bladder, stomach, intestines, reproductive organs. - Other examinations:
- No further data
- Statistics:
- Exact test (Armitage, 1971),
Bonferroni correction,
Fisher exact test - Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- effects observed, treatment-related
- Details on results:
- 2400 and 4800 mg/kg b.w./day for 5 months led to a reduced body weight gain (10 % and more) or death (no details); afterwards the dosages were reduced for the remaining 56 weeks:
--males 600 and 1200 mg/kg b.w./day,
--females 1200 and 2400 mg/kg b.w./day;
no tumors were observed except liver tumors in male mice :4 out of 16 (examined) at 600 mg/kg b.w./day; simultaneous control 1/18, pooled control 7/99. - Dose descriptor:
- dose level:
- Effect level:
- 600 mg/kg bw/day
- Sex:
- male
- Basis for effect level:
- other: m-toluidine led only to an increase in liver tumours compared to pooled controls, in male mice at the low dose
- Remarks on result:
- other:
- Remarks:
- Effect type: tumour development
- Dose descriptor:
- other: dose range
- Effect level:
- ca. 1 200 - ca. 4 800 mg/kg bw/day
- Sex:
- male
- Basis for effect level:
- other: no tumour development observed
- Remarks on result:
- other:
- Remarks:
- Effect type: no tumour development observed
- Dose descriptor:
- other: dose range
- Effect level:
- ca. 1 200 - ca. 4 800 mg/kg bw/day
- Sex:
- female
- Basis for effect level:
- other: no tumour development was observed
- Remarks on result:
- other:
- Remarks:
- Effect type: no tumour development observed
- Executive summary:
Following oral application of m-toluidine hydrochloride to male and female mice via food for 18 months and a post exposure observation period of 3 months. Based on reduction of body weight gain by 10 % compared to controls during the first 5 months the dose was reduced for the remaining treatment time. No tumour development was noted for female mice. In male mice m-toluidine hydrochloride led to an increase in liver tumours only at the lowest applied dose of 600 mg/kg bw/day when compared with pooled controls which is evaluated as a questionable result by the authors (Weissburger 1978).
In addition, the study is not performed according to the criteria of today. Limitations include study documentation in general, as well as number of animals used, level and number of dosages, treatment time and the lack of investigations during the course of the studies.
Referenceopen allclose all
400 and 800 mg/kg b.w./day for 13 weeks led to a reduced body weight gain (10 % and more) or death, therefore after 13 weeks the dosages were reduced to 200 and 400 mg/kg b.w./day for the remaining 65 weeks, no tumors were observed.
2400 and 4800 mg/kg b.w./day for 22 weeks led to a reduced body weight gain (10 % and more) or death; after 22 weeks the dosages were reduced for the remaining 56 weeks: males 600 and 1200 mg/kg b.w./day, females 1200 and 2400 mg/kg b.w./day; no tumors were observed except liver tumors in male mice (4 out of 16 examined) at 600 mg/kg b.w./day; simultaneous control 1/18, pooled control 7/99.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 200 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- other: male rats and male and female mice
- Quality of whole database:
- Limited studies in rats and mice and reported in the same publication. The provided information leads to Klimisch Score 2.
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is not justified.
Additional information
There are long term studies with m-toluidine hydrochloride available. Since the salt dissociates in aquuous solution into m-toluidine and hydrochloride these studies are relevant for m-toluidine and discussed here.
Studies are available in rats and mice that are not performed according to the criteria of today. Limitations include study design and documentation in general, as well as number of animals used, level and number of dosages, treatment time and the lack of investigations during the course of the studies:
Male rats were given daily m-toluidine hydrochloride via food 8000 and 16000 ppm (approx. 400 and 800 mg/kg bw/day), respectively. Due to significantly reduced body weight gain within 3 months lowered dosages (400 and 8000 ppm [200 amd 400 mg/lg bw/day], respectively) were given for the remaining treatment time of 15 months followed by a six month observation time without treatment.
Male and female mice received m-toluidine hydrochloride via food: 16000 and 32000 ppm (approx. 2400 and 4800 mg/kg bw/day), respectively. Due to significantly reduced body weight gain within 5 months lowered dosages were given for the remaining treatment time of 13 months: (males: 400, 8000 ppm [600, 1200 mg/kg bw/day] and females: 8000, 16000 ppm [1200, 2400 mg/kg bw/day]) followed by a 3 -months observation period without treatment..
Given the testsubstance to male rats no tumours were observed, but the application to male and female mice resulted in an increase of liver tumours in male mice only at low dosage and not at the higher dosages and no dose-effect relationship was determined. Therefore, and with regard to the lack of tumours in rats, the Beratergremium für Umweltrelevante Altstoffe (BUA 1993) concluded that a carcinogenic potency can be excluded for m-toluidine
Justification for selection of carcinogenicity via oral route
endpoint:
Limited studies in rats and mice and reported in the same
publication. the provided information leads to Klimisch Score 2
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.